Evaluation of clinical outcomes during 12 months after inclisiran initiation in patients after STEMI/non-STEMI in real-world settings in Russia. It is also planned to study the therapy effect on the lipid profile characteristics, its safety, the state of atherosclerotic plaques according to carotid ultrasound, the frequency of hospitalizations and the need for intensive follow-up.
Adult patients of both genders
Myocardial Infarction diagnosis
Dyslipidemia diagnosis
The first injection of inclisiran no later than 14 ± 5 days after the STEMI/non-STEMI
Severe oncological and somatic diseases with system and organ failure*
Competing diseases that caused emergency hospitalization (pulmonary thromboembolism, aortic dissection)
History of therapy with PCSK9 inhibitors
Active inflammatory liver disease or the levels of AST, ALT > 3 times, or total bilirubin > 2 times higher than the upper limit of norm
Novartis Pharmaceuticals
Lead sponsor